Verrica Pharmaceuticals (Verrica Pharmaceuticals) EBIT per Share : $-1.38 (TTM As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Verrica Pharmaceuticals EBIT per Share?

Verrica Pharmaceuticals's EBIT per Share for the three months ended in Dec. 2023 was $-0.48. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.38.

During the past 3 years, the average EBIT per Share Growth Rate was 4.60% per year. During the past 5 years, the average EBIT per Share Growth Rate was 7.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Verrica Pharmaceuticals's EBIT per Share or its related term are showing as below:

VRCA' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -132.6 Med: 4.6 Max: 19.8
Current: 4.6

During the past 8 years, the highest 3-Year average EBIT per Share Growth Rate of Verrica Pharmaceuticals was 19.80% per year. The lowest was -132.60% per year. And the median was 4.60% per year.

VRCA's 3-Year EBIT Growth Rate is ranked better than
52.09% of 1313 companies
in the Biotechnology industry
Industry Median: 3.5 vs VRCA: 4.60

Verrica Pharmaceuticals's EBIT for the three months ended in Dec. 2023 was $-22.31 Mil.

Verrica Pharmaceuticals EBIT per Share Historical Data

The historical data trend for Verrica Pharmaceuticals's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verrica Pharmaceuticals EBIT per Share Chart

Verrica Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-1.13

-1.59

-1.14

-0.65

-1.39

Verrica Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT per Share	Get a 7-Day Free Trial															-0.14	-0.15	-0.24	-0.50	-0.48

Verrica Pharmaceuticals EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Verrica Pharmaceuticals's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-63.033	/	45.342
=	-1.39

Verrica Pharmaceuticals's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-22.309	/	46.322
=	-0.48

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.38

Verrica Pharmaceuticals (NAS:VRCA) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Verrica Pharmaceuticals EBIT per Share Related Terms

Thank you for viewing the detailed overview of Verrica Pharmaceuticals's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Verrica Pharmaceuticals (Verrica Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verrica Pharmaceuticals Inc (NAS:VRCA) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

1NE:Germany

Address

44 West Gay Street, Suite 400, West Chester, PA, USA, 19380

Website

https://www.verrica.com

Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its lead product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a highly contagious and primarily pediatric viral skin disease, and common warts.

Executives

Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Ted White	director, officer: President and CEO	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Terry Kohler	officer: Chief Financial Officer	C/O VERRICA PHARMACEUTICALS INC., 44 WEST GAY STREET, SUITE 400, WEST CHESTER PA 19380
Christopher G. Hayes	officer: General Counsel	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Joe Bonaccorso	officer: Chief Commercial Officer	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Paul B Manning	director, 10 percent owner	200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Gary Goldenberg	director	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
A Brian Davis	officer: Chief Financial Officer	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Craig Ballaron	director	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Stalfort John A Iii	director	C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Lawrence Eichenfield	director	C/O FORTE BIOSCIENCES, INC., 1124 W. CARSON ST., MRL BLDG 3-320, TORRANCE CA 90502
Diem Nguyen	director	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Matt Davidson	10 percent owner	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Linda Palczuk	officer: Chief Operating Officer	7015 ALBERT EINSTEIN DRIVE, COLUMBIA MD 21046
Chris Degnan	officer: Chief Financial Officer	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380